EUVIMEDEUVIMED entdecken
Crossref

FDA Advisory Committee Review of Supplemental Indications and Reasons for Non-Approval, 2008-2022

Audrey D Zhang iD, Nikhil Chaudhry, Reshma Ramachandran iD, Joseph S Ross, Jason L Schwartz

Journal of Law, Medicine & Ethics · 2025 · 53 (1) · 137-144

DOI: 10.1017/jme.2025.53 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Law, Medicine & Ethics, online erschienen am 08.04.2025. Verfasst von Audrey D Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of General Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: Arnold Ventures.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study characterizes 2008-2022 FDA advisory committee discussions of new supplemental indication applications that were not approved by FDA. Discussion themes included contextual concerns unique to already-approved drugs, including insights from prior experience and concerns about off-label use, and efficacy and safety concerns also observed for new drugs. These findings highlight advisory committees’ role in transparency of regulatory decision-making, specifically for drugs already authorized for use.

Schlagwörter

Stichwörter der Autor:innen

US Food and Drug Administrationadvisory committeessupplemental indications

Autor:innen und Institutionen

  • Division of General Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States.
  • Harvard Law School, Cambridge, Massachusetts, United States.
  • General Internal Medicine, Yale School of Medicine, New Haven, Connecticut, United States.
  • Department of Health Policy and Management, Yale University, New Haven, Connecticut, United States.

ORCID-Profile: Audrey D Zhang, Reshma Ramachandran

Förderung

  • Arnold Ventures

Zitieren

APA

Zhang, A. D., Chaudhry, N., Ramachandran, R., Ross, J. S., & Schwartz, J. L. (2025). FDA Advisory Committee Review of Supplemental Indications and Reasons for Non-Approval, 2008-2022. Journal of Law, Medicine & Ethics, 53(1), 137-144. https://doi.org/10.1017/jme.2025.53

Vancouver

Zhang AD, Chaudhry N, Ramachandran R, Ross JS, Schwartz JL. FDA Advisory Committee Review of Supplemental Indications and Reasons for Non-Approval, 2008-2022. Journal of Law, Medicine & Ethics. 2025;53(1):137-144. doi:10.1017/jme.2025.53

BibTeX
@article{Zhang2025,
  author = {Zhang, Audrey D and Chaudhry, Nikhil and Ramachandran, Reshma and Ross, Joseph S and Schwartz, Jason L},
  title = {FDA Advisory Committee Review of Supplemental Indications and Reasons for Non-Approval, 2008-2022},
  journal = {Journal of Law, Medicine & Ethics},
  year = {2025},
  volume = {53},
  number = {1},
  pages = {137--144},
  doi = {10.1017/jme.2025.53}
}
Kostenlos starten →